CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Helmet CPAPWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug1027 HFNC Wiki 0.71

Correlated MeSH Terms (0)


Name (Synonyms) Correlation

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Helmet Continuous Positive Airway Pressure Versus High-Flow Nasal Cannula in COVID-19: A Pragmatic Randomised Clinical Trial

We aim to investigate whether the use of Continuous Positive Airway Pressure using a Helmet device (Helmet CPAP) will increase the number of days alive and free of ventilator within 28 days compared to the use of a High Flow Nasal Cannula (HFNC) in patients admitted to Helsingborg Hospital, Sweden, suffering from COVID-19 and an acute hypoxic respiratory failure.

NCT04395807 COVID Acute Hypoxemic Respiratory Failure Device: Helmet CPAP Device: HFNC
MeSH:Respiratory Insufficiency

Primary Outcomes

Description: Number of days alive and free of mechanical ventilation within 28 days. Patients who die within 28 days will be counted as 0 VFD. Time in ventilator will be counted in hours and rounded to whole days.

Measure: Ventilator-Free Days (VFD)

Time: 28 days

Secondary Outcomes

Description: Peripheral oxygen saturation divided by fraction of inspired oxygen

Measure: SpO2/FiO2-ratio

Time: 1 hour after randomisation

Description: Visual scale (1-10)

Measure: Patient comfort

Time: 24 hours after randomisation

Description: Min 0, Max 1

Measure: Frequency of endotracheal intubation

Time: 28 days

Description: Defined as pCO2 > 6 kPa in a venous blood gas. Min 0, Max ∞

Measure: Frequency of carbon dioxide rebreathing

Time: 28 days

Description: All-cause mortality. (180 days endpoint not in primary publication)

Measure: Days alive within

Time: 28 days and 180 days


No related HPO nodes (Using clinical trials)